To the full analysis
Buyback calculator for Gland Pharma
Gland Pharma stock: key metrics
GLAND.NSGland Pharma had an operating margin of 18.8% and a return on invested capital (ROIC) of 12.3% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | 60.6% | 46.3% | 28.0% |
| 2018 | 53.9% | 39.1% | 19.8% |
| 2019 | 52.8% | 37.1% | 22.1% |
| 2020 | 53.8% | 39.7% | 29.4% |
| 2021 | 53.5% | 41.0% | 28.8% |
| 2022 | 48.9% | 36.0% | 27.5% |
| 2023 | 48.7% | 31.9% | 21.5% |
| 2024 | 54.9% | 32.2% | 13.6% |
| 2025 | 56.2% | 30.9% | 12.4% |
| 2026 | 30.0% | 18.8% | 16.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 19.8% | 31.4% | 16.7% |
| 2018 | 13.3% | 24.4% | 11.0% |
| 2019 | 15.8% | 25.5% | 12.8% |
| 2020 | 21.2% | 36.3% | 18.9% |
| 2021 | 16.9% | 40.4% | 15.3% |
| 2022 | 16.9% | 34.7% | 15.5% |
| 2023 | 9.8% | 21.1% | 8.9% |
| 2024 | 8.9% | 21.9% | 7.2% |
| 2025 | 7.6% | 16.7% | 6.2% |
| 2026 | 9.9% | 12.3% | 8.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.